HIA
BMRN icon

HFM Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

HFM Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2K Buy
21
+11
+110% +$603 ﹤0.01% 660
2026
Q1 		$565 Hold
10
– – ﹤0.01% 623
2025
Q4 		$595 Hold
10
– – ﹤0.01% 651
2025
Q3 		$542 Buy
10
+5
+100% +$286 ﹤0.01% 625
2025
Q2 		$275 Buy
5
+2
+67% +$118 ﹤0.01% 876
2025
Q1 		$213 Buy
+3
New +$202 ﹤0.01% 606

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

HFM Investment Advisors's BMRN Position: Q2 2026 in Review

HFM Investment Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 110% in Q2 2026, buying an estimated $603 and bringing the position to 21 shares worth $1.2K. The position accounts for ﹤0.01% of the portfolio, ranked #660.

HFM Investment Advisors first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • HFM Investment Advisors held 21 shares of BioMarin Pharmaceuticals worth $1.2K as of Q2 2026.
  • HFM Investment Advisors bought 11 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $603.
  • BioMarin Pharmaceuticals made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #660 holding.
  • HFM Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.